Release Date: October 28, 2025
Expiration Date: October 28, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts on Demodex blepharitis. In this educational program, these experts review the diagnosis and management of Demodex blepharitis, including a review of available therapies.
This educational activity is an archive of the live symposium held on September 30, 2025.
Target Audience
This educational activity is directed toward optometrists, ophthalmologists, and other eye care professionals involved in the treatment of patients with Demodex blepharitis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the disease burden in patients with Demodex blepharitis
- Assess objective and subjective clinical findings to establish a diagnosis of Demodex blepharitis
- Implement targeted therapies in treatment plans to eradicate Demodex mites and improve outcomes in patients with Demodex blepharitis
Stephen C. Pflugfelder, MD
Professor
and Director of the Ocular Surface Center
Department
of Ophthalmology
Baylor
College of Medicine
Houston,
TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alcon, Dompé, Hoffman-La Roche, KALA BIO, Kowa; Grant/Research Funding: Hoffman-La Roche
Cecelia Koetting, OD, FAAO, DipABO
Assistant
Professor
Department of Ophthalmology
University of Colorado School of Medicine
Denver, CO
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alcon, Aldeyra Therapeutics, Allergan/AbbVie, Avellino, Azura Ophthalmics, Bausch + Lomb, Blinkjoy, Bruder, Claris Bio, Dompé, Eyevance/Santen Pharmaceutical, Glaukos, KALA BIO, Myze, Orasis Pharmaceuticals, Oyster Point Pharma/Viatris, RVL Pharmaceuticals, Sight Sciences, Tarsus Pharmaceuticals, Théa, Topcon, Twenty/Twenty Therapeutics, Verséa, Visus Therapeutics; Grant/Research Funding: Johnson & Johnson, Ocular Therapeutix
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.